Myeloma Crowd Radio: Maria Chaudhry, MD, Ohio State University

At last year's ASH meeting, there was excitement around a new antibody drug conjugate targeting a protein called BCMA from Glaxo Smith Klein. Results from their Phase I study showed that patients who had relapsed immunomodulators (like Revlimid), proteasome inhibitors (like Velcade) and even monoclonal antibodies (like daratumumab), responded when taking this drug alone (60% response rate).

Learn more from Dr. Maria Chaudhry of Ohio State University about current studies using this new drug and when patients could consider it in the course of their treatment. 

Thanks to our episode sponsor, Celgene.